Tier 2 — strong

Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers

P C Hollman, J H de Vries, S D van Leeuwen, M J Mengelers, M B Katan
The American journal of clinical nutrition 1995 62(6):1276-82

Bibliography

PubMed
PMID 7491892
DOI
10.1093/ajcn/62.6.1276
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandom-order crossover absorption study in ileostomy volunteers
ModelHuman intervention research
Sample9 adults with ileostomies
InterventionOnion glucosides equivalent to 89 mg quercetin, rutin equivalent to 100 mg, or quercetin aglycone 100 mg
DurationThree acute dosing days during a 12-day controlled diet
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 1995, this source examined forms, absorption and food sources. Design: Random-order crossover absorption study in ileostomy volunteers. Sample/model: 9 adults with ileostomies. The exposure or intervention was Onion glucosides equivalent to 89 mg quercetin, rutin equivalent to 100 mg, or quercetin aglycone 100 mg. Follow-up or treatment period: Three acute dosing days during a 12-day controlled diet.

Estimated intestinal absorption was higher from onion glucosides than rutin or aglycone under this method.

Absorption was inferred from ileostomy recovery and corrected degradation. It is not the fraction of unchanged quercetin reaching systemic blood or evidence of clinical benefit.

Continue with Quercetin Data Center

For topic-level interpretation, read Foods High in Quercetin: Practical Sources and Portions. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Estimated intestinal absorption was higher from onion glucosides than rutin or aglycone under this method.
  • The recorded outcome domains were Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Onion glucosides equivalent to 89 mg quercetin, rutin equivalent to 100 mg, or quercetin aglycone 100 mg; Three acute dosing days during a 12-day controlled diet.

What this study can and cannot tell us

  • Absorption was inferred from ileostomy recovery and corrected degradation. It is not the fraction of unchanged quercetin reaching systemic blood or evidence of clinical benefit.
  • A change in blood exposure or a metabolic marker is not a demonstrated improvement in symptoms, disease events or lifespan. The tested formulation and co-administered medicines matter.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Improving quercetin bioavailability: A systematic review and meta-analysis of human intervention studies
Lu Liu et al. · Food chemistry · 2025
Tier 2
Microbiological and Pharmacokinetic Aspects of a Water-Soluble Quercetin 3-O-rutinoside, EubioQuercetin: A Direct Comparison With Quercetin in In Vitro and Human Clinical Studies
Naoto Yamaguchi et al. · Journal of food science · 2025
Tier 2
Comparative Pharmacokinetics and Safety of a Micellar Chrysin-Quercetin-Rutin Formulation: A Randomized Crossover Trial
Afoke Ibi et al. · Antioxidants (Basel, Switzerland) · 2025
Tier 2
Enhanced Bioavailability and Pharmacokinetics of a Natural Self-Emulsifying Reversible Hybrid-Hydrogel System of Quercetin: A Randomized Double-Blinded Comparative Crossover Study
Ashil Joseph et al. · ACS omega · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology